Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • September 10, 2021
  • 2021 Abstracts

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL and KITE Phase III studies

Author: Ramin Tadayoni (France)

Co-authors: David Brown, Sebastian Wolf, Francesco Bandello, Andres Emanuelli, Jose Juan Escobar Barranco, Joao Figueira

Purpose

To present the 52-week results from KESTREL and KITE, two prospective Phase III studies evaluating the efficacy and safety of brolucizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME).

Setting/Venue

Patients were enrolled from 36 countries, across 197 sites.

Methods

KESTREL (NCT03481634) and KITE (NCT03481660) are two, 2-year, ongoing, double-masked, randomized, active-controlled, multicenter studies. Adults (≥18 years of age) with type 1 or type 2 diabetes mellitus, visual impairment due to DME with a best-corrected visual acuity (BCVA) score between 78 to 23 ETDRS letters, and DME involving the center of the macula with a central subfield thickness (CSFT) ≥320μm on SD-OCT in the study eye at screening were included. In KESTREL, patients were randomized 1:1:1 to brolucizumab 3 mg, brolucizumab 6 mg or aflibercept 2mg; in KITE, patients were randomized 1:1 to brolucizumab 6 mg or aflibercept 2 mg. The brolucizumab groups received 5 loading doses every 6 weeks (q6w) followed by q12w dosing in the first year, with an option to adjust to q8w if disease activity is identified at those pre-specified visits. The aflibercept group received 5 loading doses monthly followed by a fixed q8w dosing. The primary endpoint was the change from baseline in BCVA at Week 52; secondary endpoints included the proportion of brolucizumab patients maintained at q12w dosing up to Week 52 and the change from baseline in CSFT. -

Results

In both studies, the primary objective was met with brolucizumab 6mg achieving non-inferiority (margin of 4 letters) to aflibercept in change of BCVA from baseline at Week 52 (KESTREL, letters: brolucizumab 6mg +9.2 vs aflibercept +10.5, mean difference –1.3 [95% CI,–2.9, 0.3], p<0.001; KITE, letters: brolucizumab 6mg +10.6 vs aflibercept +9.4, mean difference +1.2 [95% CI,–0.6, 3.1], p<0.001). Brolucizumab 3mg did not demonstrate non-inferiority in BCVA versus aflibercept in KESTREL. More than 50% of brolucizumab 6mg patients were maintained on a q12w dosing interval through Week 52, immediately after the loading phase. For the change of CSFT from baseline over the period Week 40 through Week 52, significant improvements were achieved with brolucizumab 6mg in both studies; in KITE, brolucizumab 6mg showed superior improvements in change of CSFT over the period Week 40 through Week 52 versus aflibercept (p=0.001). At Week 52, more patients treated with brolucizumab 6mg achieved a CSFT <280µm than with aflibercept (KESTREL: 54.0% versus 40.1%; KITE: 57.5% versus 41.4%). Fewer brolucizumab 6mg patients had SRF and/or IRF versus aflibercept at Week 52 (KESTREL: 60.3% versus 73.3%; KITE: 54.2% versus 72.9%). Brolucizumab demonstrated an overall well-tolerated safety profile.

Conlusions

Results from the KESTREL and KITE studies show that brolucizumab 6 mg achieved robust vision gains and improved anatomical outcomes with more than 50% of DME patients maintained on a q12w treatment interval after loading through Week 52, and demonstrated an overall well-tolerated safety profile.

Financial Disclosure

Advisor: Alcon, Allergan, Bayer, Genentech, Novartis, Oculis, Roche, Thea, Zeiss

Comments

Additional co-authors: 7. Vishali Gupta - Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India 8. Nor Fariza Ngah - Hospital Shah Alam, Selangor, Malaysia 9. Gerald Liew - Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia 10. Raman Tuli - Department of Ophthalmology, University of Ottawa, Ottawa, Canada and The Retina Centre of Ottawa, Canada 11. Lixin Wang Wang - Novartis Pharma AG, Basel, Switzerland 12. Ying Wang Wang - Novartis Pharma AG, Basel, Switzerland 13. Emmanuel Bouillaud - Novartis Pharma AG, Basel, Switzerland 14. Eric Souied - Department of Ophthalmology, Hopital Intercommunal de Creteil, Créteil, France 15. Justus Garweg - Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland and Berner Augenklinik am Lindenhofspital and Swiss Eye Institute, Bern, Switzerland
PrevPrevious
NextNext
Euretina Logo, Links to homepage.

European Society of Retina Specialists c/o Congrex Switzerland
Reinacherstrasse 131
4053 Basel
Switzerland

T +41 61 686 77 91
F +41 61 686 77 88

General Enquires: [email protected]

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2026 All rights reserved

  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login